A Mab A Case Study In Bioprocess Development May 2026
A Monoclonal Antibody (mAb): A Case Study in Bioprocess Development
Abstract
This paper examines the end-to-end bioprocess development lifecycle for a therapeutic monoclonal antibody (mAb), from molecule selection through commercial manufacturing and regulatory considerations. It integrates upstream cell line development, bioreactor process design, downstream purification, analytical characterization, formulation, scale-up, process validation, quality-by-design (QbD), risk assessment, and techno-economic analysis. Emphasis is placed on decision points that balance product quality, manufacturability, cost, and regulatory compliance, illustrated with data-driven examples and recommended best practices.
Hydrophobic interaction (HIC) – optional: Butyl Sepharose – used only if aggregates > 1.5% after CEX. A Mab A Case Study In Bioprocess Development
13. Techno-Economic Analysis (TEA)
- Cost drivers: upstream titer and yield, protein A resin cost and lifetime, fill-finish economics, labor and facility.
- Example model (illustrative):
Case Study Insight: A Mab’s unique CDR regions caused a conformational shift at low pH. The team screened over 12 elution buffers and found that adding 0.5 M arginine and 50 mM sodium acetate at pH 3.8, followed by immediate neutralization to pH 5.0, reduced aggregates to 2.5%. A Monoclonal Antibody (mAb): A Case Study in
The final step in the bioprocess development of A Mab was the development of a stable formulation. A Mab was formulated in a buffer containing a stabilizer, a surfactant, and a polysorbate. The formulation was optimized to achieve: Cost drivers: upstream titer and yield, protein A